Challenges and advances towards the rational design of mRNA vaccines

Trends in Molecular Medicine

Volumn 19, Issue 12, 2013, Pages 705-713

  Pollard, Charlotte ^a,b   De Koker, Stefaan ^b   Saelens, Xavier ^b,c   Vanham, Guido ^a,d   Grooten, Johan ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cellular immunity; Cytotoxic T cells; Dendritic cell; MRNA; Nucleic acid based vaccines; Vaccination

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; ERYTHROPOIETIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 1; MRNA VACCINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENCY; ENCAPSULATION; EX VIVO STUDY; GENETIC TRANSFECTION; HELPER CELL; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; REVIEW; RNA STABILITY; TECHNOLOGY; TUMOR IMMUNITY; VACCINATION;

CELLULAR IMMUNITY; CYTOTOXIC T CELLS; DENDRITIC CELL; MRNA; NUCLEIC ACID-BASED VACCINES; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS; RNA, MESSENGER; VACCINES;

EID: 84888436279     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.09.002     Document Type: Review

References (50)

1. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12:265-277.
2. Mellman I., et al. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
3. Pascolo S. Vaccination with messenger RNA (mRNA). Handb. Exp. Pharmacol. 2008, 183:221-235.
4. Boudreau J.E., et al. Engineering dendritic cells to enhance cancer immunotherapy. Mol. Ther. 2011, 19:841-853.
5. Vanham G., Van Gulck E. Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?. Retrovirology 2012, 9:72.
6. Martinon F., et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 1993, 23:1719-1722.
7. Hoerr I., et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 2000, 30:1-7.
8. Scheel B., et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 2006, 36:2807-2816.
9. Lu D., et al. Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors. Cancer Gene Ther. 1994, 1:245-252.
10. Kreiter S., et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010, 70:9031-9040.
11. Kreiter S., et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 2011, 19:6132-6142.
12. Van Lint S., et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012, 7:1661-1671.
13. Hess P.R., et al. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol. Immunother. 2006, 55:672-683.
14. Mockey M., et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 2007, 14:802-814.
15. Fotin-Mleczek M., et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 2011, 34:1-15.
16. Rejman J., et al. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J. Control. Release 2010, 147:385-391.
17. Varkouhi A.K., et al. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151:220-228.
18. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731-745.
19. Pasquinelli A.E., et al. Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. RNA 1995, 1:957-967.
20. Stepinski J., et al. Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA 2001, 7:1486-1495.
21. Kuhn A.N., et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 2010, 17:961-971.
22. Holtkamp S., et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006, 108:4009-4017.
23. Kormann M.S.D., et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 2011, 29:154-157.
24. Karikó K., et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175.
25. Ge J., Yu Y.-T. RNA pseudouridylation: new insights into an old modification. Trends Biochem. Sci. 2013, 4:210-218.
26. Pollard C., et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 2013, 1:251-259.
27. + T cells in immunity to viruses. Nat. Rev. Immunol. 2012, 12:136-148.
28. Bonehill A., et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 2004, 172:6649-6657.
29. Forsbach A., et al. Sequence-specific TLR8-dependent immune response. J. Immunol. 2012, 180:3729-3738.
30. Karikó K., et al. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 2004, 279:12542-12550.
31. Ceppi M., et al. Double-stranded secondary structures on mRNA induce type I interferon (IFN α/β) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J. Gene Med. 2005, 7:452-465.
32. Botos I., et al. The toll-like receptor 3:dsRNA signaling complex. Biochim. Biophys. Acta 2009, 1789:667-674.
33. Schlee M., et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
34. Schmidt A., et al. 5'-Triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12067-12072.
35. Sabbah A., et al. Activation of innate immune antiviral response by NOD2. Nat. Immunol. 2009, 10:1073-1080.
36. Kim D-H., et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 2004, 22:321-325.
37. Rajagopal D., et al. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010, 115:1949-1957.
38. + Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206:1589-1602.
39. Pichlmair A., Reis e Sousa C. Innate recognition of viruses. Immunity 2007, 27:370-383.
40. Diken M., et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 2011, 18:702-708.
41. Lelouard H., et al. Regulation of translation is required for dendritic cell function and survival during activation. J. Cell Biol. 2007, 179:1427-1439.
42. Petsch B., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 2012, 30:1210-1216.
43. Weide B., et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 2008, 31:180-188.
44. Weide B., et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 2009, 32:498-507.
45. + immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 2011, 19:990-999.
46. Kadowaki N., et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-869.
47. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
48. Lande R., Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann. N. Y. Acad. Sci. 2010, 1183:89-103.
49. De Koker S., et al. Designing polymeric particles for antigen delivery. Chem. Soc. Rev. 2011, 40:320-339.
50. Rettig L., et al. Particle size and activation threshold: a new dimension of danger signaling. Blood 2010, 115:4533-4541.